دورية أكاديمية
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
| العنوان: | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis |
|---|---|
| المؤلفون: | Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó-Maristany, F., Galván, P., Martínez, O., Adamo, B., Vidal, M., Muñoz, M., Fernández-Martinez, A., Rognoni, C., Griguolo, G., Guarneri, V., Conte, P.F., Locci, M., Brase, J.C., Gonzalez-Farre, B., Villagrasa, P., De Placido, S., Schiff, R., Veeraraghavan, J., Rimawi, M.F., Osborne, C.K., Pernas, S., Perou, C.M., Carey, L.A., Prat, A. |
| المصدر: | Cancer Treatment Reviews, 84 |
| بيانات النشر: | W.B. Saunders Ltd |
| سنة النشر: | 2020 |
| المجموعة: | Carolina Digital Repository (UNC - University of North Carolina) |
| مصطلحات موضوعية: | HER2-positive, Biomarker, Pathologic complete response, PAM50, Breast cancer, HER2-Enriched |
| الوصف: | Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based regimens. Here, we present a meta-analysis to validate the association of the HER2-E subtype with pCR following anti-HER2-based neoadjuvant treatments with or without chemotherapy (CT). Methods: A systematic literature search was performed in February 2019. The primary objective was to compare the association between HER2-E subtype (versus others) and pCR. Selected secondary objectives were to compare the association between 1) HER2-E subtype and pCR in CT-free studies, 2) HER2-E subtype within hormone receptor (HR)-negative and HR+ disease and 3) HR-negative disease (versus HR+) and pCR in all patients and within HER2-E subtype. A random-effect model was applied. The Higgins’ I2 was used to quantify heterogeneity. Results: Sixteen studies were included, 5 of which tested CT-free regimens. HER2-E subtype was significantly associated with pCR in all patients (odds ratio [OR] = 3.50, p < 0.001, I2 = 33%), in HR+ (OR = 3.61, p < 0.001, I2 = 1%) and HR-negative tumors (OR = 2.28, p = 0.01, I2 = 47%). In CT-free studies, HER2-E subtype was associated with pCR in all patients (OR = 5.52, p < 0.001, I2 = 0%) and in HR + disease (OR = 4.08, p = 0.001, I2 = 0%). HR-negative status was significantly associated with pCR compared to HR + status in all patients (OR = 2.41, p < 0.001, I2 = 30%) and within the HER2-E subtype (OR = 1.76, p < 0.001, I2 = 0%). Conclusions: The HER2-E biomarker identifies patients with a higher likelihood of achieving a pCR following neoadjuvant anti-HER2-based therapy beyond HR status and CT use. Future trial designs to escalate or de-escalate systemic therapy in HER2+ disease should consider this genomic biomarker. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.17615/hgdw-v761Test; https://cdr.lib.unc.edu/downloads/k0698j870?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/k0698j870Test |
| DOI: | 10.17615/hgdw-v761 |
| الإتاحة: | https://doi.org/10.17615/hgdw-v761Test https://cdr.lib.unc.edu/downloads/k0698j870?file=thumbnailTest https://cdr.lib.unc.edu/downloads/k0698j870Test |
| حقوق: | http://rightsstatements.org/vocab/InC/1.0Test/ |
| رقم الانضمام: | edsbas.AB940317 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17615/hgdw-v761 |
|---|